Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States

Pediatric Infectious Disease Journal

Volumn 32, Issue 8, 2013, Pages 871-880

  Payton, Terry ^a   Girgenti, Douglas ^b   Frenck, Robert W ^c   Patterson, Scott ^b   Love, Jack ^b   Razmpour, Ahmad ^b   Sidhu, Mohinder S ^b   Emini, Emilio A ^b   Gruber, William C ^b   Scott, Daniel A ^b  

^a Northwest Arkansas Pathology Associ PA   (United States)

^b PFIZER INC   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

13 valent pneumococcal conjugate vaccine; immunogenicity; safety

Indexed keywords

7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; ANTIPYRETIC AGENT; BACTERIAL VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA TETANUS TOXOID ACELLULAR PERTUSSIS INACTIVATED POLIOVIRUS HEPATITIS B VIRUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; IMMUNOGLOBULIN G; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS VACCINE;

ACUTE SINUSITIS; ALLERGIC REACTION; ANTIBODY BLOOD LEVEL; ARTICLE; BRONCHIOLITIS; CELLULITIS; CHILD; CLINICAL DEVELOPMENT PLAN; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CONJUGATION; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; FEMALE; FEVER; FOOT MALFORMATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OTALGIA; OTITIS MEDIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEBORRHEIC DERMATITIS; SEROTYPE; STANDARDIZED MORTALITY RATIO; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VACCINATION; VACCINE PRODUCTION; VOMITING;

ANTIBODIES, BACTERIAL; ANTIPYRETICS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FEVER; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INFANT; MALE; PNEUMOCOCCAL VACCINES; UNITED STATES;

EID: 84880590223     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182906499     Document Type: Article

References (34)

1. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec. 2007;82:93-104.
2. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
3. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295:1668-1674.
4. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
5. Harboe ZB, Valentiner-Branth P, Benfield TL, et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine. 2010;28:2642-2647.
6. Vestrheim DF, Høiby EA, Bergsaker MR, et al. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine. 2010;28:2214-2221.
7. Centers for Disease Control and Prevention. Emergence of antimicrobialresistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep. 2007;56:1077-1080.
8. Pilishvili T, Lexau C, Farley MM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
9. GAVI's PneumoADIP. Pneumococcal Regional Serotype Distribution for Pneumococcal AMC TPP [GAVI Alliance website]. November 30, 2008. Available at: http://www.gavialliance.org/library/documents/amc/tpp-codebook/. Accessed May 16, 2012.
10. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346-1354.
11. GAVI's PneumoADIP. Pneumococcal Global Serotype Project: Summary report of Stage 1/Version 1 analysis [PneumoACTION web site]. October 18, 2007. Available at: http://www.preventpneumo.org/pdf/ GSP%20Summary%20for%20SAGE%20Nov6-8%202007-Oct%2019-07.pdf. Accessed May 9, 2012.
12. Bender JM, Ampofo K, Korgenski K, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis. 2008;46:1346-1352.
13. Abdelnour A, Soley C, Guevara S, et al. Streptococcus pneumoniae serotype 3 among Costa Rican children with otitis media: clinical, epidemiological characteristics and antimicrobial resistance patterns. BMC Pediatr. 2009;9:52.
14. Porat N, Soley C, Marengolciene MM, et al. An international serotype 3 clone causing pediatric noninvasive infections in Israel, Costa Rica, and Lithuania. Pediatr Infect Dis J. 2008;27:709-712.
15. Kieninger DM, Kueper K, Steul K, et al.; 006 Study Group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192-4203.
16. Bryant KA, Block SL, Baker SA, et al.; PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;125:866-875.
17. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017-1026.
18. Yeh SH, Gurtman A, Hurley DC, et al.; 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493-e505.
19. Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29:e80-e90.
20. Vanderkooi OG, Scheifele DW, Girgenti D, et al.; Canadian PCV13 Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31:72-77.
21. Quataert S, Martin D, Anderson P, et al. A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol Invest. 2001;30:191-207.
22. Quataert SA, Kirch CS, Wiedl LJ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol. 1995;2:590-597.
23. Quataert SA, Rittenhouse-Olson K, Kirch CS, et al. Assignment of weightbased antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f). Clin Diagn Lab Immunol. 2004;11:1064-1069.
24. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25:3816-3826.
25. Baker S, Hu BT, Hackell J, et al. Effect of addition of heterologous pneumococcal polysaccharide 22F to the Wyeth/WHO pneumococcal polysaccharide ELISA on IgG assignments for infant sera. Paper presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases; April 2-6, 2006; Alice Springs, Central Australia, Australia. Abstract 285.
26. Wiens BL, Iglewicz B. On testing equivalence of three populations. J Biopharm Stat. 1999;9:465-483.
27. Chan IS, Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics. 1999;55:1202-1209.
28. Epidemiology, Assessment and Program Development Branch, MCAH Program, Center for Family Health, California Department of Public Health. Statewide Infant Mortality Data [California Department of Public Health]. Available at: http://www.cdph.ca.gov/data/statistics/Documents/MO-MCAH- StatewideInfantMortalityData.pdf. Accessed May 17, 2012.
29. Grimprel E, Laudat F, Patterson S, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine. 2011;29:9675-9683.
30. Frenck R Jr, Thompson A, Yeh SH, et al.; 3011 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30:1086-1091.
31. Heidelberger M, Jann K, Jann B, et al. Relations between structures of three K polysaccharides of Escherichia coli and cross-reactivity in antipneumococcal sera. J Bacteriol. 1968;95:2415-2417.
32. Heidelberger M, Nimmich W. Additional immunochemical relationships of capsular polysaccharides of Klebsiella and pneumococci. J Immunol. 1972;109:1137-1144.
33. World Health Organization. Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy, of pneumococcal conjugate vaccines. Replacement of TRS 927. Annex 2. [World Health Organization]. Available at: http://www.who.int/biologicals/areas/vaccines/ pneumo/Pneumo-final-23APRIL-2010.pdf. Accessed May 17, 2012.
34. Wise RP, Iskander J, Pratt RD, et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA. 2004;292:1702-1710.